MedTrace Logo

Pre-admission Hyperglycemia and Its Effect on Morbidity and Mortality

NCT00871832 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2013-06-06

No results posted yet for this study

Summary

It is currently standard of care in many Medical and Surgical ICU's to institute a nurse driven insulin protocol in maintaining tight glucose control in the critical patient. Many articles have been written to address this topic. However, there is no current data regarding the use of glycohemoglobin as a marker of risk of morbidity and mortality. In our study we would like to determine whether or not the HbA1C could be used as a marker of morbidity and mortality. The HbA1C is a simple blood test that may be added on to any CBC collection tube; a blood sample that critical patients have drawn up to several times a day. The investigators would analyze this information in respect to the rest of the clinical data collected regarding the patient's illness.

Conditions

Sponsors & Collaborators

  • Staten Island University Hospital

    collaborator OTHER

  • Northwell Health

    lead OTHER

Principal Investigators

  • Mario Castellanos, MD · Staten Island University Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-05-31
Primary Completion
2010-03-31
Completion
2010-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00871832 on ClinicalTrials.gov